Jeanne Erdmann is an award-winning health and science writer based in Wentzville, Mo. A member of Association of
Health Care Journalists board of directors, she is the chair of the organization’s Freelance Committee. Her work has appeared in Discover, Women’s Health, Aeon, Slate, The Washington Post, Nature, Nature Medicine and other publications. You can follow her at @jeanne_erdmann.
Jeanne Erdmann
From this contributor
Analysis pins down prevalence of mental health conditions in autism
Eight mental health conditions occur unusually often in autistic people, a new analysis suggests.
Analysis pins down prevalence of mental health conditions in autism
By
Jeanne Erdmann
7 October 2019 | 2 min read
Drug screen reveals potential treatments for Rett syndrome
An experimental leukemia drug and a chemical in black pepper ease breathing and movement problems in a mouse model of Rett syndrome.
Drug screen reveals potential treatments for Rett syndrome
By
Jeanne Erdmann
11 September 2019 | 4 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read